Eptinezumab
drugOn this page
Also known as ALD-403ALD403Eptinezumab jjmrEptinezumab-jjmrVyepti
Summary
Eptinezumab (CHEMBL3833320) is an approved antibody (ATC N02CD05); indicated across 3 conditions including migraine disorder and diabetic neuropathy.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: N02CD05
- Indications: 3 conditions
- Clinical trials: 29
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3833320 |
| Name | Eptinezumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | N02CD05 |
Also known as: ALD-403, ALD403, Eptinezumab, Eptinezumab jjmr, Eptinezumab-jjmr, Vyepti, EPTINEZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| migraine disorder | 4 | MONDO:0005277 | MONDO:0005277 |
| diabetic neuropathy | 2 | MONDO:0006626 | MONDO:0001583 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 29.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 15 |
| PHASE1 | 5 |
| Not specified | 4 |
| PHASE4 | 3 |
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06701526 | PHASE4 | ACTIVE_NOT_RECRUITING | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications |
| NCT05284019 | PHASE4 | TERMINATED | Real World Effectiveness of Eptinezumab in Participants With Migraine |
| NCT05452239 | PHASE4 | COMPLETED | A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache |
| NCT04965675 | PHASE3 | RECRUITING | A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine |
| NCT05164172 | PHASE3 | RECRUITING | A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine |
| NCT05897320 | PHASE3 | RECRUITING | A Study of Eptinezumab in Pediatric Participants With Episodic Migraine |
| NCT06428838 | PHASE3 | NOT_YET_RECRUITING | Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context |
| NCT07191145 | PHASE3 | NOT_YET_RECRUITING | Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) |
| NCT02559895 | PHASE3 | COMPLETED | A Multicenter Assessment of ALD403 in Frequent Episodic Migraine |
| NCT02974153 | PHASE3 | COMPLETED | Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine |
| NCT02985398 | PHASE3 | COMPLETED | An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine |
| NCT04152083 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine |
| NCT04418765 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments |
| NCT04688775 | PHASE3 | COMPLETED | Eptinezumab in Participants With Episodic Cluster Headache |
| NCT04772742 | PHASE3 | COMPLETED | Eptinezumab in Adults With Migraine and Medication Overuse Headache |
| NCT04921384 | PHASE3 | COMPLETED | Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine |
| NCT05064371 | PHASE3 | COMPLETED | Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan |
| NCT05064397 | PHASE3 | COMPLETED | A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH) |
| NCT02275117 | PHASE2 | COMPLETED | A Multicenter Assessment of ALD403 in Chronic Migraine |
| NCT05937152 | PHASE2 | WITHDRAWN | A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy |
| NCT01579383 | PHASE1 | COMPLETED | Safety Tolerability and Pharmacokinetics of ALD403 |
| NCT01772524 | PHASE1 | COMPLETED | Safety, Efficacy and Pharmacokinetics of ALD403 |
| NCT04336449 | PHASE1 | COMPLETED | Eptinezumab in Healthy Japanese Subjects |
| NCT04537429 | PHASE1 | COMPLETED | A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab |
| NCT05045781 | PHASE1 | COMPLETED | Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects |
| NCT05334927 | Not specified | RECRUITING | China HeadAche DIsorders RegiStry |
| NCT06212661 | Not specified | ENROLLING_BY_INVITATION | Migraine Medication Effects on Urinary Symptoms |
| NCT05635604 | Not specified | COMPLETED | Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients. |
| NCT07035197 | Not specified | COMPLETED | Facilitators and Barriers to Eptinezumab Administration in Thailand |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: migraine disorder